Dermatomyositis and meningioma in the same patient

Almodóvar, Raquel; Lindo, D.P.; Martı́n, H; Mazzuchelli, Ramón; Pardo, Javier; Quirós, Francisco Javier; Zarco, Pedro

doi:10.1016/j.reuma.2011.06.009

Cited by 4 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various authors reported reduced or absent esophageal motility sometimes extending to the lower esophageal sphincter [ 29 , 38 , 114 ]. Most studies used manometry [ 24 , 29 , 38 , 59 , 85 , 90 , 98 , 105 , 114 , 117 , 118 , 119 , 122 , 129 , 130 ] some also VFSS, barium swallow or scintigraphy [ 62 , 73 , 81 , 89 , 99 , 104 , 120 , 121 , 124 , 125 , 127 ] to detect esophageal impairment.…”

Section: Resultsmentioning

confidence: 99%

“…There are several articles reporting positive therapeutic effects of immunomodulatory medication on symptoms and/or on findings of objective swallowing evaluations. These include intravenous methylprednisolone pulse therapy [ 19 , 33 , 70 , 81 , 87 , 134 , 154 , 155 , 156 , 157 , 158 , 159 ], methotrexate [ 30 , 76 , 89 , 124 , 136 , 154 , 159 , 160 , 161 ], long-term prednisone/prednisolone [ 29 , 30 , 33 , 59 , 64 , 70 , 74 , 76 , 81 , 83 , 84 , 87 , 89 , 101 , 103 , 111 , 118 , 122 , 124 , 134 , 136 , 143 , 154 , 158 , 159 , 161 , 162 , 163 , 164 , 165 ,…”

Section: Resultsmentioning

confidence: 99%

“…IIM can result in impairment of the oral [29,[58][59][60][61][62][63][64], pharyngeal [7,23,24,27,29,[31][32][33]44, and esophageal [24,29,38,59,62,73,81,85,89,90,93,95,98,99,101,[103][104][105]112,[114][115][116][117][118][119][120][121][122][123][124][125][126][127][128][129]…”

Section: Inflammation Of Swallowing Musclesmentioning

confidence: 99%

See 2 more Smart Citations

The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis

Labeit

Pawlitzki

Ruck

et al. 2020

JCM

View full text Add to dashboard Cite

(1) Background: Dysphagia is a clinical hallmark and part of the current American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) diagnostic criteria for idiopathic inflammatory myopathy (IIM). However, the data on dysphagia in IIM are heterogenous and partly conflicting. The aim of this study was to conduct a systematic review on epidemiology, pathophysiology, outcome and therapy and a meta-analysis on the prevalence of dysphagia in IIM. (2) Methods: Medline was systematically searched for all relevant articles. A random effect model was chosen to estimate the pooled prevalence of dysphagia in the overall cohort of patients with IIM and in different subgroups. (3) Results: 234 studies were included in the review and 116 (10,382 subjects) in the meta-analysis. Dysphagia can occur as initial or sole symptom. The overall pooled prevalence estimate in IIM was 36% and with 56% particularly high in inclusion body myositis. The prevalence estimate was significantly higher in patients with cancer-associated myositis and with NXP2 autoantibodies. Dysphagia is caused by inflammatory involvement of the swallowing muscles, which can lead to reduced pharyngeal contractility, cricopharyngeal dysfunction, reduced laryngeal elevation and hypomotility of the esophagus. Swallowing disorders not only impair the quality of life but can lead to serious complications such as aspiration pneumonia, thus increasing mortality. Beneficial treatment approaches reported include immunomodulatory therapy, the treatment of associated malignant diseases or interventional procedures targeting the cricopharyngeal muscle such as myotomy, dilatation or botulinum toxin injections. (4) Conclusion: Dysphagia should be included as a therapeutic target, especially in the outlined high-risk groups.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis

Labeit

Pawlitzki

Ruck

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…A number of paraneoplastic symptoms have been attributed to cranial meningiomas such as optic neuropathy, dermatomyositis, Cushing's syndrome, nephrotic syndrome, or hypocalcemia. [29121318] This case may add peripheral small fiber polyneuropathy to the potential list of paraneoplastic symptoms. None of the cases with paraneoplastic symptoms in the literature had distant metastases from the intracranial meningioma.…”

Section: Discussionmentioning

confidence: 99%

Paraneoplastic symptoms caused by extracranial meningioma metastases?

Mindermann

2016

Surg Neurol Int

View full text Add to dashboard Cite

Background:There are only few reports on distant metastases of cranial meningiomas WHO I. In one-third of the cases, distant metastases seem to be clinically silent. This is the first case of distant metastases which may have manifested with a paraneoplastic syndrome.Case Description:A 52-year-old white male patient was diagnosed with distant metastases to the bones and liver 11 and 12 years following craniotomy and removal of a tentorial meningioma WHO I. At that time, the patient had developed paresthesia, unsteady gait, and a slight cognitive impairment, which in retrospect had no other explanation than that of a paraneoplastic syndrome. Eighteen years following craniotomy, a small intracranial tumor rest is under control following two single session radiosurgery treatments. At present, the patient has a multitude of bone and liver metastases, which seem to cause his paraneoplastic symptoms.Conclusion:Screening for malignancies in patients with paraneoplastic symptoms and a history of cranial meningioma should include screening for distant metastases from the meningioma.

show abstract

“…Bis heute existieren keine einheitlichen und verbindlichen Nachsorge-und Tumor-Richtlinien [5,8]. Eine Zusammenfassung gängiger Empfehlungen sowie der häufigsten assoziierten Tumoren [2,[9][10][11][12][13][14] und Risikofaktoren [2,5,6,10,[15][16][17][18][19] ist dem Online-Supplement zu entnehmen.…”

Section: Introductionunclassified